<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100748</url>
  </required_header>
  <id_info>
    <org_study_id>CP130-2001</org_study_id>
    <nct_id>NCT02100748</nct_id>
  </id_info>
  <brief_title>A Study of TRV130 for the Treatment of Pain After Bunionectomy</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Multiple-dose, Adaptive, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain After Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevena Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trevena Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the analgesic efficacy of IV TRV130 compared with&#xD;
      placebo in patients with acute postoperative pain after bunionectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the analgesic efficacy of IV TRV130 compared with&#xD;
      placebo in patients with acute postoperative pain after bunionectomy. The results section&#xD;
      also includes data from the morphine arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Weighted Average (TWA) Change From Baseline in Pain Score Over 48 Hours Between TRV130 and Placebo</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NPRS), with higher numbers indicating a higher pain intensity, administered over 48 hours. Time weighted average change from baseline is calculated using the following: time weighted sum of pain intensity differences (SPID) divided by a constant (48 hours) to yield values on the 0-10 NPRS.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>TRV130 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRV130 1 mg IV Q4H x 48 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRV130 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRV130 2 mg IV Q4H x 48 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRV130 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRV130 3 mg IV Q4H x 48 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRV130 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRV130 4 mg IV Q4H x 48 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine 4 mg IV Q4H x 48 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (D5W) IV Q4H x 48 h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRV130</intervention_name>
    <description>TRV130 1 - 4 mg will be administered every 4 hours</description>
    <arm_group_label>TRV130 1 mg</arm_group_label>
    <arm_group_label>TRV130 2 mg</arm_group_label>
    <arm_group_label>TRV130 3 mg</arm_group_label>
    <arm_group_label>TRV130 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine 4 mg will be administered every 4 hours</description>
    <arm_group_label>Morphine</arm_group_label>
    <other_name>Morphine sulphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered every 4 hours</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Dextrose 5% in water</other_name>
    <other_name>D5W</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has undergone primary, unilateral, first metatarsal bunionectomy (osteotomy and&#xD;
             internal fixation) with no additional collateral procedures.&#xD;
&#xD;
          -  Experiences a pain intensity rating of â‰¥ 4 on an 11 point NRS&#xD;
&#xD;
          -  Able to provide written informed consent before any study procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA Physical Status Classification System classification of P3 or worse&#xD;
&#xD;
          -  Has surgical or post-surgical complications.&#xD;
&#xD;
          -  Has clinically significant medical conditions or history of such conditions that may&#xD;
             interfere with the interpretation of efficacy, safety, or tolerability data obtained&#xD;
             in the trial, or may interfere with the absorption, distribution, metabolism, or&#xD;
             excretion of drugs.&#xD;
&#xD;
          -  Has previously participated in another TRV130 clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Skobieranda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trevena Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 23, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <results_first_submitted>August 20, 2020</results_first_submitted>
  <results_first_submitted_qc>September 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <disposition_first_submitted>July 7, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>July 7, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 11, 2017</disposition_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>moderate to severe acute pain</keyword>
  <keyword>bunionectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part A - TRV130 1 mg</title>
          <description>TRV130 1 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="P2">
          <title>Part A - TRV130 2 mg</title>
          <description>TRV130 2 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="P3">
          <title>Part A - TRV130 3 mg</title>
          <description>TRV130 3 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="P4">
          <title>Part A - TRV130 4 mg</title>
          <description>TRV130 4 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="P5">
          <title>Part A - Morphine</title>
          <description>Morphine 4 mg IV Q4H x 48 h&#xD;
Morphine: Morphine 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="P6">
          <title>Part A - Placebo</title>
          <description>Placebo (D5W) IV Q4H x 48 h&#xD;
Placebo: Placebo will be administered every 4 hours</description>
        </group>
        <group group_id="P7">
          <title>Part B - TRV130 0.5 mg</title>
          <description>TRV130 0.5 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="P8">
          <title>Part B - TRV130 1 mg</title>
          <description>TRV130 1 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="P9">
          <title>Part B - TRV130 2 mg</title>
          <description>TRV130 2 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="P10">
          <title>Part B - TRV130 3 mg</title>
          <description>TRV130 3 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="P11">
          <title>Part B - Placebo</title>
          <description>Placebo (D5W) IV Q3H x 48 h&#xD;
Placebo: Placebo will be administered every 3 hours</description>
        </group>
        <group group_id="P12">
          <title>Part B - Morphine</title>
          <description>Morphine 4 mg IV Q4H x 48 h&#xD;
Morphine: Morphine 4 mg will be administered every 4 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="23"/>
                <participants group_id="P7" count="20"/>
                <participants group_id="P8" count="38"/>
                <participants group_id="P9" count="36"/>
                <participants group_id="P10" count="31"/>
                <participants group_id="P11" count="28"/>
                <participants group_id="P12" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="23"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="34"/>
                <participants group_id="P9" count="33"/>
                <participants group_id="P10" count="29"/>
                <participants group_id="P11" count="26"/>
                <participants group_id="P12" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A - TRV130 1 mg</title>
          <description>TRV130 1 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="B2">
          <title>Part A - TRV130 2 mg</title>
          <description>TRV130 2 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="B3">
          <title>Part A - TRV130 3 mg</title>
          <description>TRV130 3 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="B4">
          <title>Part A - TRV130 4 mg</title>
          <description>TRV130 4 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="B5">
          <title>Part A - Morphine</title>
          <description>Morphine 4 mg IV Q4H x 48 h&#xD;
Morphine: Morphine 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="B6">
          <title>Part A - Placebo</title>
          <description>Placebo (D5W) IV Q4H x 48 h&#xD;
Placebo: Placebo will be administered every 4 hours</description>
        </group>
        <group group_id="B7">
          <title>Part B - TRV130 0.5 mg</title>
          <description>TRV130 0.5 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="B8">
          <title>Part B - TRV130 1 mg</title>
          <description>TRV130 1 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="B9">
          <title>Part B - TRV130 2 mg</title>
          <description>TRV130 2 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="B10">
          <title>Part B - TRV130 3 mg</title>
          <description>TRV130 3 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="B11">
          <title>Part B - Placebo</title>
          <description>Placebo (D5W) IV Q3H x 48 h&#xD;
Placebo: Placebo will be administered every 3 hours</description>
        </group>
        <group group_id="B12">
          <title>Part B - Morphine</title>
          <description>Morphine 4 mg IV Q4H x 48 h&#xD;
Morphine: Morphine 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="25"/>
            <count group_id="B6" value="23"/>
            <count group_id="B7" value="20"/>
            <count group_id="B8" value="38"/>
            <count group_id="B9" value="36"/>
            <count group_id="B10" value="31"/>
            <count group_id="B11" value="28"/>
            <count group_id="B12" value="39"/>
            <count group_id="B13" value="333"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="12.52"/>
                    <measurement group_id="B2" value="41.8" spread="12.06"/>
                    <measurement group_id="B3" value="40.3" spread="13.33"/>
                    <measurement group_id="B4" value="42.1" spread="13.66"/>
                    <measurement group_id="B5" value="41.5" spread="12.53"/>
                    <measurement group_id="B6" value="43.5" spread="9.94"/>
                    <measurement group_id="B7" value="38.6" spread="11.38"/>
                    <measurement group_id="B8" value="43.3" spread="11.02"/>
                    <measurement group_id="B9" value="36.7" spread="12.23"/>
                    <measurement group_id="B10" value="37.5" spread="10.58"/>
                    <measurement group_id="B11" value="39.9" spread="11.04"/>
                    <measurement group_id="B12" value="42.6" spread="13.09"/>
                    <measurement group_id="B13" value="41.2" spread="12.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="34"/>
                    <measurement group_id="B9" value="32"/>
                    <measurement group_id="B10" value="29"/>
                    <measurement group_id="B11" value="25"/>
                    <measurement group_id="B12" value="31"/>
                    <measurement group_id="B13" value="297"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="28"/>
                    <measurement group_id="B9" value="24"/>
                    <measurement group_id="B10" value="24"/>
                    <measurement group_id="B11" value="22"/>
                    <measurement group_id="B12" value="27"/>
                    <measurement group_id="B13" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="11"/>
                    <measurement group_id="B13" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other - Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="9"/>
                    <measurement group_id="B13" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="30"/>
                    <measurement group_id="B9" value="28"/>
                    <measurement group_id="B10" value="20"/>
                    <measurement group_id="B11" value="22"/>
                    <measurement group_id="B12" value="30"/>
                    <measurement group_id="B13" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="38"/>
                    <measurement group_id="B9" value="36"/>
                    <measurement group_id="B10" value="31"/>
                    <measurement group_id="B11" value="28"/>
                    <measurement group_id="B12" value="39"/>
                    <measurement group_id="B13" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Weighted Average (TWA) Change From Baseline in Pain Score Over 48 Hours Between TRV130 and Placebo</title>
        <description>Pain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NPRS), with higher numbers indicating a higher pain intensity, administered over 48 hours. Time weighted average change from baseline is calculated using the following: time weighted sum of pain intensity differences (SPID) divided by a constant (48 hours) to yield values on the 0-10 NPRS.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A - TRV130 1 mg</title>
            <description>TRV130 1 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
          </group>
          <group group_id="O2">
            <title>Part A - TRV130 2 mg</title>
            <description>TRV130 2 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
          </group>
          <group group_id="O3">
            <title>Part A - TRV130 3 mg</title>
            <description>TRV130 3 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
          </group>
          <group group_id="O4">
            <title>Part A - TRV130 4 mg</title>
            <description>TRV130 4 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
          </group>
          <group group_id="O5">
            <title>Part A - Morphine</title>
            <description>Morphine 4 mg IV Q4H x 48 h&#xD;
Morphine: Morphine 4 mg will be administered every 4 hours</description>
          </group>
          <group group_id="O6">
            <title>Part A - Placebo</title>
            <description>Placebo (D5W) IV Q4H x 48 h&#xD;
Placebo: Placebo will be administered every 4 hours</description>
          </group>
          <group group_id="O7">
            <title>Part B - TRV130 0.5 mg</title>
            <description>TRV130 0.5 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
          </group>
          <group group_id="O8">
            <title>Part B - TRV130 1 mg</title>
            <description>TRV130 1 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Part B - TRV130 2 mg</title>
            <description>TRV130 2 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
          </group>
          <group group_id="O10">
            <title>Part B - TRV130 3 mg</title>
            <description>TRV130 3 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
          </group>
          <group group_id="O11">
            <title>Part B - Placebo</title>
            <description>Placebo (D5W) IV Q3H x 48 h&#xD;
Placebo: Placebo will be administered every 3 hours</description>
          </group>
          <group group_id="O12">
            <title>Part B - Morphine</title>
            <description>Morphine 4 mg IV Q4H x 48 h&#xD;
Morphine: Morphine 4 mg will be administered every 4 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time Weighted Average (TWA) Change From Baseline in Pain Score Over 48 Hours Between TRV130 and Placebo</title>
          <description>Pain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NPRS), with higher numbers indicating a higher pain intensity, administered over 48 hours. Time weighted average change from baseline is calculated using the following: time weighted sum of pain intensity differences (SPID) divided by a constant (48 hours) to yield values on the 0-10 NPRS.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="38"/>
                <count group_id="O9" value="36"/>
                <count group_id="O10" value="31"/>
                <count group_id="O11" value="28"/>
                <count group_id="O12" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="2.11"/>
                    <measurement group_id="O2" value="-3.1" spread="2.25"/>
                    <measurement group_id="O3" value="-2.6" spread="1.82"/>
                    <measurement group_id="O4" value="-3.3" spread="1.51"/>
                    <measurement group_id="O5" value="-4.1" spread="2.02"/>
                    <measurement group_id="O6" value="-3.2" spread="1.79"/>
                    <measurement group_id="O7" value="-3.0" spread="2.36"/>
                    <measurement group_id="O8" value="-2.9" spread="2.64"/>
                    <measurement group_id="O9" value="-3.7" spread="2.10"/>
                    <measurement group_id="O10" value="-5.0" spread="2.14"/>
                    <measurement group_id="O11" value="-2.8" spread="2.12"/>
                    <measurement group_id="O12" value="-4.0" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Part A - TRV130 1 mg</title>
          <description>TRV130 1 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="E2">
          <title>Part A - TRV130 2 mg</title>
          <description>TRV130 2 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="E3">
          <title>Part A - TRV130 3 mg</title>
          <description>TRV130 3 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="E4">
          <title>Part A - TRV130 4 mg</title>
          <description>TRV130 4 mg IV Q4H x 48 h&#xD;
TRV130: TRV130 1 - 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="E5">
          <title>Part A - Morphine</title>
          <description>Morphine 4 mg IV Q4H x 48 h&#xD;
Morphine: Morphine 4 mg will be administered every 4 hours</description>
        </group>
        <group group_id="E6">
          <title>Part A - Placebo</title>
          <description>Placebo (D5W) IV Q4H x 48 h&#xD;
Placebo: Placebo will be administered every 4 hours</description>
        </group>
        <group group_id="E7">
          <title>Part B - TRV130 0.5 mg</title>
          <description>TRV130 0.5 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="E8">
          <title>Part B - TRV130 1 mg</title>
          <description>TRV130 1 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="E9">
          <title>Part B - TRV130 2 mg</title>
          <description>TRV130 2 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="E10">
          <title>Part B - TRV130 3 mg</title>
          <description>TRV130 3 mg IV Q3H x 48 h&#xD;
TRV130: TRV130 0.5 - 4 mg will be administered every 3 hours</description>
        </group>
        <group group_id="E11">
          <title>Part B - Placebo</title>
          <description>Placebo (D5W) IV Q3H x 48 h&#xD;
Placebo: Placebo will be administered every 3 hours</description>
        </group>
        <group group_id="E12">
          <title>Part B - Morphine</title>
          <description>Morphine 4 mg IV Q4H x 48 h&#xD;
Morphine: Morphine 4 mg will be administered every 4 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="31" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="31" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="28" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="20" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="31" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="20" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="23" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="22" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="17" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="17" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperhydrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pruritus Generalized</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kelly Arscott</name_or_title>
      <organization>Trevena, Inc.</organization>
      <phone>6103548840</phone>
      <email>karscott@trevena.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

